Exelixis, Inc. (ticker: EXEL, exchange: NASDAQ Global Market (.O))
News Release -
Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Two oral presentations, two poster discussion presentations, three poster
SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) announced today that data from clinical trials of the company's
investigational compounds XL647, XL184, XL765 and XL880 will be presented at
the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which
will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical
trial data will be described in two oral presentations (XL184 and XL765), two
poster presentations and discussions (XL647), and three poster presentations
(XL647 and XL880).
- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in patients
with advanced malignancies, including medullary thyroid cancer, will be presented
on Sunday, June 1, 2008, starting at 10 a.m. local time (Abstract #3522).
- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients with
advanced solid tumors will be presented on Saturday, May 31, 2008, starting
at 1:15 p.m. local time (Abstract #3510).
Poster Presentations and Discussions
- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in NSCLC
patients with acquired resistance to EGFR tyrosine kinase inhibitors will
be presented on Monday, June 2, 2008, during the 8 a.m.-noon session (Abstract
- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed daily
in patients with advanced solid malignancies will be presented on Saturday,
May 31, 2008, during the 8 a.m.-noon session (Abstract #3528).
- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in clinically
selected NSCLC patients enriched for the presence of EGFR mutations will be
presented on Sunday, June 1, 2008, during the 2-6 p.m. session (Abstract #8053).
- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in patients with
papillary renal cell carcinoma will be presented on Saturday, May 31, 2008,
during the 8 a.m.-noon session (Abstract #5103).
- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in MET amplified,
poorly differentiated gastric cancer will be presented on Monday, June 2,
2008, during the 8 a.m.-2 p.m. session (Abstract #4572).
* XL880 was selected by GlaxoSmithKline in December 2007 for further development
Exelixis, Inc. is a development-stage biotechnology company dedicated to the
discovery and development of novel small molecule therapeutics for the treatment
of cancer and other serious diseases. The company is leveraging its fully integrated
drug discovery platform to fuel the growth of its development pipeline, which
is primarily focused on cancer. Currently, Exelixis' broad product pipeline
includes investigational compounds in phase 2 and phase 1 clinical development.
Exelixis has established strategic corporate alliances with major pharmaceutical
and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb
Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information,
please visit the company's web site at http://www.exelixis.com.
Exelixis and the Exelixis logo are registered U.S. trademarks.
SOURCE Exelixis, Inc.
CONTACT: Charles Butler, Senior Director, Corporate Communications &
Investor Relations, +1-650-837-7277, firstname.lastname@example.org, or Soleil Harrison,
Senior Manager, Corporate Communications, +1-650-837-7012,
email@example.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com